Kaitlyn D’Onofrio

DocwireNews

Patients with active rheumatoid arthritis (RA) and inadequate response to methotrexate (MTX-IR) could have positive clinical outcomes with sarilumab plus MTX, according to a recent study in a Japanese population.&ldquo;Sarilumab is a human immunoglobulin G1 anti-interleukin-6 (IL-6) receptor monoclonal antibody that blocks IL-6 from binding to membrane-bound and soluble IL-6 receptor &alpha;,&rdquo; the study authors wrote. &ldquo;This bridging study assessed the efficacy and safety of sarilumab + methotrexate (MTX) in Japanese patients with active rheumatoid arthritis (RA) and inadequate response to MTX (MTX-IR).&rdquo;For the trial, eligible patients had to be aged between 20 and 75 years and have moderately to severely active disease, defined as &ge;&thinsp;eight of 68 tender joints and &ge;&thinsp;six of 66 swollen joints, and high-sensitivity CRP &ge;&thinsp;0.6&thinsp;mg/dL. MTX-IR was defined as &ge;&thinsp;three&thinsp;months&rsquo; disease duration despite continuous six-week MTX treatment at least six weeks prior to screening. Patients with uncontrolled concomitant disease, severe systemic RA, other autoimmune or inflammatory systemic or localized joint diseases, current/recurrent infections, or past history of nonresponse to prior therapy with a TNF antagonist or a biologic treatment were not included in the trial.A total of 243 patients were randomized 2:2:1:1 to one of the following treatment options, in combination with MTX: subcutaneous sarilumab 150&thinsp;mg every 2&thinsp;weeks (q2w), sarilumab 200&thinsp;mg q2w, placebo switching to sarilumab 150&thinsp;mg q2w + MTX at 24&thinsp;weeks, or placebo switching to sarilumab 200&thinsp;mg q2w at 24&thinsp;weeks. The study&rsquo;s primary endpoint was how many patients successfully attained 24-week American College of Rheumatology 20% improvement criteria (ACR20).https://twitter.com/AntibodyNews/status/1108626680623427586<h2>Sarilumab Outperforms Placebo</h2>After 24 weeks, the proportion of patients who achieved ACR20 response rates were as follows: sarilumab 150 mg, 67.9%; sarilumab 200 mg, 57.5%; and placebo, 14.8%. No deaths occurred, and placebo to sarilumab 150 mg group experienced no adverse effects; in the other groups, adverse events rates were 9.9% in the sarilumab 150 mg group, 6.3% in the sarilumab 200 mg group, and 13.3% in the placebo to sarilumab 200 mg group. Infection incidence ranged from 52.5% to 67.9%. The sarilumab 150 mg group had five serious infections, while the placebo to 200 mg sarilumab group had one. There was no association between absolute neutrophil count &lt;&thinsp;1.0 Giga/l and infection, which presented in 13.6% of the sarilumab 150 mg group and 7.5% of the sarilumab 200 mg group.The study authors concluded, &ldquo;Despite the availability of a wide range of treatment options for RA, there remains an unmet need globally for the treatment of patients who are intolerant or refractory to current therapies. These important findings show that a new treatment option that has been assessed globally is also effective for Japanese patients with RA.&rdquo;<blockquote class="twitter-tweet" data-width="500" data-dnt="true">
Open Access UCL Research: Evaluation of the efficacy and safety of sarilumab combination therapy in patients with rheumatoid arthritis with inadequate response to conventional disease-modifying antirheumatic drugs or tumour necrosis factor &alpha; inhibitors <a href="https://t.co/XbZwBZzuer">https://t.co/XbZwBZzuer</a>
&mdash; UCL Discovery (@ucl_discovery) <a href="https://twitter.com/ucl_discovery/status/1108775886780858374?ref_src=twsrc%5Etfw">March 21, 2019</a>
</blockquote><script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script>

Jeffrey Perl, MD

Joel M. Topf, MD, FACP

Thoughts From the 2025 Lazarus Award Winner

NKF Spring Clinical Meetings 2025

Brandon Twyford

DESTINY-Breast09 Demonstrates First-Line Superiority of Enhertu Plus Pertuzumab in HER2-Positive Metastatic Breast Cancer

HER2 Breast Cancer

Trodelvy Plus Keytruda Significantly Improves Progression-Free Survival in PD-L1+ mTNBC, Phase III Data Show

Triple-Negative Breast Cancer

Latest News

Combo Sarilumab plus Methotrexate May Benefit RA Patients

Rheumatoid Arthritis

Patients with active rheumatoid arthritis (RA) and inadequate response to methotrexate (MTX-IR) could have positive clinical outcomes with sarilumab plus MTX, according to a ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HR Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe